Abstract 48P
Background
A2A receptor (A2AR) is a key mediator of adenosine immunosuppression. Inupadenant is a highly selective A2AR antagonist, which maintains full potency at the high levels of adenosine found in tumors. We recently reported that B cells are a novel cellular target of inupadenant (Martinoli et al., AACR 2023). Here, we further investigate how inupadenant modulates humoral responses in vitro, ex vivo and in vivo.
Methods
Inupadenant was assessed through: in vitro generation of antibody secreting cells (ASCs) from memory B cells isolated from human PBMCs; ex vivo tumor culture of tumor slices derived from human lung cancer; and single cell RNA sequencing (scRNAseq) on isolated healthy tonsil B cells. The A2AR agonist CGS-21680 (in vitro and scRNAseq) or ATP (ex vivo) were added to trigger A2AR signaling, and B cells were stimulated with CpG (scRNAseq) or CD40L (ex vivo). Cell cultures were assessed by flow cytometry and Legendplex. The CT26-OVA model was used to study tumor-targeted immunoglobulin (Ig) production and immune infiltration by ELISA and RNAseq.
Results
Inupadenant rescued the A2AR-mediated inhibition of B cell maturation into ASCs and Ig production in both in vitro and ex vivo systems. In CT26-OVA mice, inupadenant increased OVA-specific IgGs in blood and tumor, as well as B cells and ASCs in spleen and tumor. Besides ASCs, germinal center (GC) B cells were the main B cell subset affected by A2AR signaling in human tonsil, as supported by (i) the highest number of differentially expressed genes observed in these subsets after CGS-21680 stimulation, and (ii) by their highest expression of the A2AR gene, ADORA2A. Inupadenant completely reverted the effect of CGS-21680 in ASCs and GC B cells, including the expression of AICDA, a critical gene for somatic hypermutation and class-switch recombination in GCs.
Conclusions
These data support the notion that inupadenant restores or even potentiates B cell maturation toward ASCs and GC reactions in both secondary lymphoid organs as well as tumor in the presence of A2AR signaling. This process is essential to produce high affinity antibodies and potentially for sustained anti-tumor immunity. Additional work is ongoing to confirm this novel mechanism in inupadenant-treated patients.
Legal entity responsible for the study
iTeos Therapeutics.
Funding
iTeos Therapeutics.
Disclosure
P. Tieppo, M. Mercier, S. Jung, D. Carbonez, L. Chaible, R. Marillier, F. Strozzi, H. Shehade, Y. McGrath, M. Rossetti: Financial Interests, Personal, Full or part-time Employment: iTeos Therapeutics; Financial Interests, Personal, Stocks/Shares: iTeos Therapeutics. M. Dieu-Nosjean: Financial Interests, Personal, Speaker, Consultant, Advisor: iTeos Therapeutics.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session